Aortic Valve Insufficiency
Conditions
Brief summary
The purpose of this study is to assess the efficacy of sacubitril-valsartan compared to the combination of ARB/CCB on left ventricular remodeling in patients with chronic aortic valve regurgitation.
Detailed description
After being informed consent about the study and potential risk, all patients giving written informed consent will undergo a 1 month screening period to determine eligibility for study entry. At week 0, patients who meet the eligibility requirements will be randomized in an open-label manner in a 1:1 ratio to sacubitril-valsartan or amlodipine/losartan.
Interventions
DRUGSacubitril-valsartan
50mg\ 100mg twice daily
DRUGAmlodipine-losartan
amlodipine/losartan 2.5/25mg \ 5/100mg once daily
Sponsors
Samsung Medical Center
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
20 Years to 90 Years
Healthy volunteers
No
Inclusion criteria
1. Participant over 20 years of age who has not been hospitalized for heart failure 2. Participant with hypertension or systolic blood pressure 125 mmHg or higher 3. NYHA I 4. Participant with chronic severe aortic regurgitation (VCW \>0.6cm) 5. Participant with AV regurgitant volume ≥ 60mL or effective regurgitant orifice area ≥ 0.3 cm2 6. Participant with left ventricular ejection fraction ≥ 55%
Exclusion criteria
1. A history of hypersensitivity or allergy to clinical trial drugs or similar compounds or ARB/NEP inhibitors 2. History of angioedema 3. Patients with an ascending aorta dilated by more than 55 mm 4. Patients with aortic valve insufficiency due to hereditary aortic disease (Marfan syndrome, Ehlers-Danlos syndrome) 5. Patients with moderate to severe aortic stenosis 6. Patients with claustrophobia or with metallic implants unsuitable for magnetic resonance imaging 7. History of acute heart failure within 6 weeks and dyspnea of NYHA II or higher 8. Symptomatic hypotension or SBP \< 100 mmHg at screening 9. Patients with renal failure (Estimated GFR \< 30 mL/min/1.73 m2) or on dialysis 10. Significant increase in blood potassium level (Potassium \> 5 mmol/L) 11. Blood AST or ALT value is more than twice the upper limit of normal or symptoms and signs of cirrhosis (history of hepatic coma, history of esophageal varices, history of symptomatic ascites) 12. In case of acute coronary syndrome, stroke, thoracic surgery, and percutaneous coronary angioplasty within 3 months 13. If aortic valve surgery is scheduled within the next 6 months 14. In case of severe mitral valve disease 15. Patients with primary hyperaldosteronism 16. If a woman of childbearing potential has not used double contraception 17. Women who are currently pregnant or lactating 18. When it is judged that there are clinically significant abnormalities in physical examination, diagnostic examination, electrocardiogram, etc. at the time of the screening visit
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change of left ventricular end-diastolic volume index from baseline to 12 months follow-up | Baseline and month 12 | Change = \[LVEDV on CMR at 12 months\]-\[LVEDV on CMR at baseline\] |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change of EROA of aortic valve regurgitation from baseline to 12 months follow-up. | Baseline and month 12 | Measurement of regurgitant volume of AR is derived from Doppler imaging on echocardiography. Change = \[regurgitant volume at 12 months\]-\[regurgitant volume at baseline\] |
| Change of LV end-systolic volume from baseline to 12 months follow-up. | Baseline and month 12 | Change = \[LVEDV at 12 months\]-\[LVEDV at baseline\] |
| Change of regurgitant volume of aortic valve regurgitation from baseline to 12 months follow-up. | Baseline and month 12 | Change = \[regurgitant volume at 12 months\]-\[regurgitant volume at baseline\] |
| Change of NT-proBNP level from baseline to 12 months follow-up. | Baseline and month 12 | Change =\[NT-proBNP at 12 months\]-\[NTproBNP at baseline\] |
| Aortic valve replacement or repair operation | During 12 months after enrollment | Any surgical event for correction of AR |
| Holodiastolic flow reversal in the proximal abdominal aorta and descending thoracic aorta from baseline to 12 months follow-up | Baseline and month 12 | presence or absence of holodiastolic flow reversal in the proximal abdominal and descending thoracic aorta on echocardiography |
Countries
South Korea
Contacts
Primary ContactEun Kyoung Kim, MD. PhD
Backup ContactSung Ji Park, MD, PhD
Outcome results
None listed